Correspondence 0001104659-24-091144 from AEON Biopharma, Inc. (AEON) (CIK 0001837607) (AEON)

AEON Biopharma, Inc. (AEON) (CIK 0001837607)
Date: Aug. 20, 2024 · CIK: 0001837607 · Accession: 0001104659-24-091144

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-281562

Date

August 20, 2024

Author

Not clearly detected

Form

CORRESP

Company

AEON Biopharma, Inc. (AEON) (CIK 0001837607)

Letter

AEON Biopharma, Inc.

5 Park Plaza, Suite 1750

Irvine, California 92614

August 20, 2024

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-6010

Attention: Jessica Dickerson

Re: AEON Biopharma, Inc.

Registration Statement on Form S-3

File No. 333-281562

Ladies and Gentlemen:

In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-3 filed on August 15, 2024 (the “Registration Statement”) of AEON Biopharma, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m. Eastern Time on August 21, 2024, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Drew Capurro at (714) 755-8008.

Thank you for your assistance in this matter.

Very truly yours,
AEON BIOPHARMA, INC.

Show Raw Text

CORRESP
1
filename1.htm

AEON Biopharma, Inc.

5 Park Plaza, Suite 1750

Irvine, California 92614

August 20, 2024

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-6010

Attention: Jessica Dickerson

 Re: AEON Biopharma, Inc.

    Registration Statement on Form S-3

    File No. 333-281562

Ladies and Gentlemen:

In accordance with Rule 461
of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration
of the effective date of the Registration Statement on Form S-3 filed on August 15, 2024 (the “Registration Statement”)
of AEON Biopharma, Inc. (the “Company”). We respectfully request that the Registration Statement
become effective as of 4:00 p.m. Eastern Time on August 21, 2024, or as soon as practicable thereafter. Once the Registration
Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling
Drew Capurro at (714) 755-8008.

Thank you for your assistance in this matter.

 Very truly yours,

  AEON BIOPHARMA, INC.

  By:
                           /s/ Alex Wilson

               Alex Wilson

               EVP, Chief Legal Officer & Secretary

cc: B. Shayne Kennedy, Latham & Watkins LLP

  Drew Capurro, Latham & Watkins LLP

SecProbe.io